Virus injection aims to stop melanoma before it spreads
NCT ID NCT06216938
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests an injection of a modified herpes virus (RP1) directly into high-risk melanoma tumors. The goal is to see if it can kill cancer cells and reduce the chance of the cancer spreading to nearby lymph nodes. About 25 adults with thick or ulcerated melanoma will receive the treatment before standard lymph node surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can new drug cocktails reawaken the immune system against melanoma?
- Could a Six-Month exercise and diet plan shield muscle during melanoma treatment?
- Quitting before the knife: which Stop-Smoking aid works best for cancer patients?
- Can a One-Two punch of immune boosters revive cancer treatment?
- Can a modified herpes virus turn the tide against advanced cancer?
- Can your genes predict your melanoma risk?